Health Condition 1: C220- Liver cell carcinoma
Conditions
Interventions
None listed
Sponsors
AstraZeneca Pharma India Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adult female or male patients aged =18 years or ‘adults’ according to the age of majority as defined by the local regulations at index diagnosis 2. Patients or legal representative (unless a waiver is granted) willing and be able to provide informed consent according to local regulations. For deceased patients at study entry, informed consent is not mandatory. 3. Patients with radiologically or histopathologically confirmed diagnosis (at index date) of unresectable BCLC stage B HCC, not considered eligible for initial loco-regional therapya or stage C advanced or metastatic disease between 01 January 2017 and 31 December 2019. 4. Availability of at least 12 months of follow-up data (from the index date) in the medical records at the participating site, unless patient died within the first 12 months of diagnosis.
Exclusion criteria
Exclusion criteria: 1. Patients with BCLC stage D HCC at index diagnosis 2. Patients with concomitant cancer, at the time of diagnosis of unresectable HCC, except for the nonmetastatic nonmelanoma skin cancers or in situ or benign neoplasms; a cancer is considered concomitant if it occurs within 5 years of HCC diagnosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To describe the OS rate in patients with unresectable HCC including estimates of survival rates at 6, 12, and 18 months and at 2 yearsTimepoint: One Year | — |
Secondary
| Measure | Time frame |
|---|---|
| To describe the management patterns in patients with unresectable HCC To describe the demographic and clinical characteristics of patients with unresectable HCCTimepoint: One Year | — |
Countries
Brazil, Egypt, Hong Kong, India, Republic of Korea, Saudi Arabia, Singapore, Taiwan, United Arab Emirates
Contacts
Public ContactAmit Kumar
AstraZeneca Pharma India Ltd
Outcome results
None listed